. 2020 Oct 26;12(1):197–209. doi: 10.1007/s13300-020-00945-4

Table 1.

Baseline demographics and clinical characteristics of patients enrolled in the study

Baseline demographics and clinical characteristics	BOT group^a	BB group^a
Full analysis set (N)	186	58
Male, n (%)	98 (52.7)	34 (58.6)
Age (years)	64 ± 9 n = 185	63 ± 11 n = 58
Disease duration (years)	15 ± 8 n = 182	16 ± 9 n = 58
HbA1_c (%)	8.5 ± 1.2 n = 184	8.2 ± 1.2 n = 58
Weight (kg)	93.4 ± 19.2 n = 172	101.1 ± 21.3 n = 58
BMI (kg/m²)	33.0 ± 6.2 n = 172	34.9 ± 6.9 n = 58
FPG (mg/dL)	162.4 ± 46.8 n = 154	154.2 ± 49.0 n = 58
Systolic blood pressure (mmHg)	136.3 ± 19.5 n = 165	137.6 ± 16.9 n = 58
Lipid profile (mg/dL)
Total cholesterol	168.7 ± 41.3 n = 150	171.4 ± 42.8 n = 52
HDL cholesterol	45.8 ± 12.5 n = 145	47.2 ± 11.1 n = 49
Triglycerides	152.2 ± 81.6 n = 147	160.0 ± 95.6 n = 52
Hypoglycemia episodes
Symptomatic	0.3 ± 1.1 n = 99	1.3 ± 2.0 n = 32
Severe	0.3 ± 1.1 n = 99	0 n = 32

Baseline demographics and clinical characteristics

BOT group^a

BB group^a

Full analysis set (N)

186

Male, n (%)

98 (52.7)

34 (58.6)

Age (years)

64 ± 9

n = 185

63 ± 11

n = 58

Disease duration (years)

15 ± 8

n = 182

16 ± 9

n = 58

HbA1_c (%)

8.5 ± 1.2

n = 184

8.2 ± 1.2

n = 58

Weight (kg)

93.4 ± 19.2

n = 172

101.1 ± 21.3

n = 58

BMI (kg/m²)

33.0 ± 6.2

n = 172

34.9 ± 6.9

n = 58

FPG (mg/dL)

162.4 ± 46.8

n = 154

154.2 ± 49.0

n = 58

Systolic blood pressure (mmHg)

136.3 ± 19.5

n = 165

137.6 ± 16.9

n = 58

Lipid profile (mg/dL)

Total cholesterol

168.7 ± 41.3

n = 150

171.4 ± 42.8

n = 52

HDL cholesterol

45.8 ± 12.5

n = 145

47.2 ± 11.1

n = 49

Triglycerides

152.2 ± 81.6

n = 147

160.0 ± 95.6

n = 52

Hypoglycemia episodes

Symptomatic

0.3 ± 1.1

n = 99

1.3 ± 2.0

n = 32

Severe

0.3 ± 1.1

n = 99

n = 32

Values in table are presented as the mean ± standard deviation (SD), unless indicated otherwise

BMI Body mass index, FPG fasting plasma glucose, HbA1_c glycated glucose, HDL high-density lipoprotein

^aThe patient groups comprised those patients with type 2 diabetes mellitus (T2DM) whose previous therapy prior to the switch to IDeglira (fixed-ratio combination of basal insulin [BI] and glucagon-like peptide-1 receptor agonist [GLP1-RA]) was either BI with or without concomitant ≥ 1 oral antidiabetic drugs (OADs) (BOT group) or those treated according to the basal bolus protocol (BI and rapid-acting insulin treatment; BB group)